Tonix Pharmaceuticals Holding Corp. Stock Analysis & AI Score
Tonix Pharmaceuticals Holding Corp. (TNXP) has an ST Score of 45.1 (C+), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $27.00 price target (+178.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Tonix Pharmaceuticals Holding Corp. (TNXP) has an ST Score of 45.1 (C+), driven by its Forecast (A) and held back by its Momentum (F). Analysts rate it Buy with a $27.00 price target (+178.4% upside).
- Strongest
- ForecastA
- Weakest
- MomentumF
All factor grades
- ForecastA
- Financial StrengthB
- GrowthB
- ValuationC
- ProfitabilityD+
- MomentumF
- Piotroski3/9
Contact
TNXP stock: frequently asked questions
What is TNXP's ST Score?
Tonix Pharmaceuticals Holding Corp. (TNXP) has an ST Score of 45.1 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TNXP a buy, hold, or sell?
Analysts rate TNXP a Buy, with a price target of $27.00 (+178.4% vs the current price). Our ST Score grades it C+ (45.1/100). The ST Score is a data-driven signal, not a recommendation.
What are TNXP's factor grades?
Valuation C, Profitability D+, Financial Strength B, Momentum F, Growth B, Forecast A.
What is TNXP's valuation grade?
Tonix Pharmaceuticals Holding Corp. (TNXP) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TNXP's growth grade?
Tonix Pharmaceuticals Holding Corp. (TNXP) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TNXP's profitability grade?
Tonix Pharmaceuticals Holding Corp. (TNXP) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TNXP's financial strength grade?
Tonix Pharmaceuticals Holding Corp. (TNXP) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TNXP?
The average analyst price target for Tonix Pharmaceuticals Holding Corp. (TNXP) is $27.00 from 7 analysts, which is +178.4% versus the recent price of $9.70.
What is TNXP's Piotroski score?
Tonix Pharmaceuticals Holding Corp. (TNXP) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.